自身骨髓移植治疗急性髓系白血病——附7例报告

Autologous Bone Marrow Transplantation in Acute Myeloid Leukemias: A Report of 7 Cases

对7例急性髓系白血病(AML)完全缓解期(CR)患者进行自身骨髓移植(ABMT)洽疗,结果7例患者均恢复造血,无1例近期死亡。ABMT后随访情况表明,标危组2例在CR1期移植者已无病生存26及18月,在CR2期移植的2例中1例已超过30月,另1例于移植后9月死于他因,并无白血病复发迹象。3例高危组患者中2例于移植后5月复发,另1例已持续CR5.5月,目前尚在观察中。提示ABMT对标危组AML(CR1及CR2期)患者的疗效优于高危组。

Seven patients with acute myeloid leukemias(AML) in complete remission(CR) were treated with high dose chemotherapy and/or total body irradiation (TBI) followed by autologous bone marrow transplantation (ABMT) .The clinical status of the 7 cases at ABMT were as follows. 5 in CR1(2 with standard risks and 3 with high risks)and 2 in CR2(both with standard risks).The conditioning regimens used for ABMT were cyclophosphamide plus TBI in 3 cases , high dose busulfan plus cyclophosphamide in 3 cases, and BACT program chemotherapy in 1 case. All 7 cases showed hemopoietic reconstitution after ABMT; no death occured within the post-transplantation aplasia period,but hepatotoxicity was observed with high dose busulfan. Up to December, 1989, 2 patients in CR1 with standard risk receiving transplants had survived, disease free, for 26 and 18 months, respectively; one of 2 patients in CR2 with standard risk receiving transplants had survived for 30 months, and the other died at the 9th month after ABMT with no sign of leukemia relapse.Two of the 3 patients with high risk relapsed at 5 months post-ABMT and the third was in continuous CR for 5.5 months.